5 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 4 Phase 1, 4 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Completed 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow Myeloma-Multiple: new trials by email Literature Review of Myeloma-Multiple trials Research Report on Myeloma-Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Selinexor, Dexamethasone Oral, Daratumumab - Multiple Myeloma, Myeloma Multiple | Phase 2 | Active not recruiting | US Oncology Research | 73 | 2021-09-10 | 2025-01-16 |
| Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma Avelumab, External beam radiotherapy - Myeloma, Multiple, Myeloma-Multiple | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2019-10-17 | 2021-05-12 |
| T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma Cyclophosphamide, Fludarabine, Rimiducid - Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 13 | 2019-06-13 | 2021-09-09 |
| T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma Cyclophosphamide, Fludarabine, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells - Myeloma-Multiple, Myeloma, Plasma-Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2018-09-14 | 2026-06-16 |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients Carfilzomib, Daratumumab, Lenalidomide - Myeloma Multiple, Myeloma, Plasma-Cell | Phase 2 | Completed | Tel-Aviv Sourasky Medical Center | 41 | 2018-05-02 | 2022-01-27 |
| Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma Tocilizumab, Melphalan, Fludarabine - Multiple Myeloma, Myeloma-Multiple | Early Phase 1 | Withdrawn | Washington University School of Medicine | 2015-12-01 | 2016-07-12 | |
| Study of the Immune Response After Vaccination in Multiple Myeloma Patients Multiple Myeloma, Myeloma, Multiple | Completed | Wake Forest University Health Sciences | 19 | 2014-12-30 | 2024-10-03 | |
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells - Myeloma, Plasma-Cell, Myeloma-Multiple | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2014-08-12 | 2019-10-08 |
| Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma Adoptive Immunotherapy, Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy - Myeloma, Plasma-Cell, Myeloma-Multiple | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 34 | 2010-11-10 | 2019-12-10 |
Multiple Myeloma (9) · Neoplasms, Plasma Cell (2) · Influenza, Human (1) · Neoplasms (1) · Pneumonia (1)
Blood Protein Disorders (9) · Cardiovascular Diseases (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Hemorrhagic Disorders (9) · Hemostatic Disorders (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphoproliferative Disorders (9) · Neoplasms by Histologic Type (9) · Paraproteinemias (9) · Vascular Diseases (9) · Neoplasms (8) · Neoplasms, Plasma Cell (7) · Infections (1)
Cyclophosphamide (4) · fludarabine (4) · fludarabine phosphate (4) · Automobiles (3) · Receptors, Chimeric Antigen (3) · Dexamethasone (2) · Lenalidomide (2) · bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine (2) · daratumumab (2) · AP 1903 reagent (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Immunotherapy, Adoptive (1) · Melphalan (1) · Mycophenolic Acid (1)
National Cancer Institute (NCI) (5) · Tel-Aviv Sourasky Medical Center (1) · US Oncology Research (1) · Wake Forest University Health Sciences (1) · Washington University School of Medicine (1)
United States (7) · Israel (1)
James N Kochenderfer, M.D. (3) · John F DiPersio, M.D., Ph.D. (1) · Mark Roschewski, M.D. (1) · Michael Thompson, MD, PhD (1) · Robert M Rifkin, MD, FACP (1) · Steven Z Pavletic, M.D. (1) · Yael Cohen, MD (1)
PMID 26370838, PMID 27412889, PMID 29812997, PMID 33619369, PMID 41702648